CA2915838C — Bicyclic bromodomain inhibitors
Assigned to Zenith Epigenetics Ltd · Expires 2023-04-18 · 3y expired
What this patent protects
The invention provides novel substituted, bicyclic compounds which are useful as inhibitors of extra terminal domain BET protein function by binding to bromodomains, such as compounds of Formula IIb' or Formula IId', or a stereoisomer, tautomer, pharmaceutically acceptable salt, …
USPTO Abstract
The invention provides novel substituted, bicyclic compounds which are useful as inhibitors of extra terminal domain BET protein function by binding to bromodomains, such as compounds of Formula IIb' or Formula IId', or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof. The pharmaceutical compositions comprising such compounds are for the prevention and treatment of diseases and conditions that are associated with bromodomain and extra terminal domain (BET) proteins. Ilb' Ild'
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.